Patent Protection in Russia: Implications of USPTO Actions and U.S. Sanctions for Safeguarding IP Rights
Course Details
- smart_display Format
On-Demand
- signal_cellular_alt Difficulty Level
- work Practice Area
Patent
- event Date
Tuesday, May 31, 2022
- schedule Time
1:00 p.m. ET./10:00 a.m. PT
- timer Program Length
90 minutes
-
This 90-minute webinar is eligible in most states for 1.5 CLE credits.
This CLE webinar will review the implications of U.S sanctions on Russia and recent U.S. Patent and Trademark Office (USPTO) actions for patent owners and applicants. The panel will also address the steps that Russia has taken in response and what they may mean for U.S. companies holding patents in Russia. Finally, the panel will discuss what U.S. companies might do to protect their patents and minimize the risk of infringement.
Mr. Solberg works with businesses and entities ranging from startups and universities to Fortune 500 companies to protect their technologies through patent prosecution, enforcement and competitive patent analyses in a variety of industries, including medical device, biotech and agriculture. He manages and implements strategies for both emerging and significant patent and application portfolios, drafts and prosecutes patent applications in various technologies, performs due diligence investigations of IP portfolios in M&A deals, evaluates the validity and enforceability of patents, and advises on infringement issues. He also drafts and negotiates various technology agreements, such as licenses, assignments and agreements related to research, collaboration and consulting. In addition to his expertise in patent prosecution, IP transactions, opinions and due diligence, Mr. Solberg has experience in complex IP litigation, providing support and drafting briefs in conjunction with IP litigators. He is a registered patent attorney, licensed to practice before the United States Patent and Trademark Office.
Mr. Mathison builds patent assets for businesses and universities through patent prosecution. His practice spans all manner of electronics and software and mechanical patents, including flourishing expertise in electronic medical devices. Mr. Mathison counsels startups, Fortune 100 companies, high-net worth individuals, and small and medium sized businesses looking to build something new and protect it against other market players. Those looking for real business-sense protection of inventive concepts, whether in pursuing patents, fortifying trade secrets, or technological protection, find a trusted and articulate counselor in Mr. Mathison.
Prior to his position at BMS, Mr. Wilusz established a patent law firm in Washington State. His clients included academic institutions and large and small companies. He procures and defends intellectual property rights and negotiates transactions and acquisitions for biopharma interests. Those interests include small molecule, biotech, and cellular therapies, AI and ML initiatives for drug discovery, clinical innovations, and patient disease monitoring tools. Mr. Wilusz has collaborated to optimize exclusivity for more than 100 products with combined annual sales of over 80 billion dollars for his clients. He has secured IP rights for assets that span drug discovery, clinical development, and patient centric innovations. Mr. Wilusz has previously held roles as Senior VP of IP and Licensing at Makai Biotechnology, Life Cycle Management Lead at Sanofi, and VP of IP at Novartis. He is a USPTO registered patent attorney.
In response to Russia’s invasion of Ukraine, the U.S. government imposed sanctions on several Russian entities, some of which affect U.S. companies with patent holdings and applications in Russia. For example, payments to Russia's patent and trademark office are or will be forbidden by U.S. sanctions. The same applies in some respects to the Eurasian Patent Organization, which is also based in Russia. This not only impacts patent applications but also annual maintenance fee payments on granted Russian patents. Paying these fees would violate the sanctions, but not paying them would result in the patents expiring.
Russia's response to sanctions has been to punish U.S companies and those from other "unfriendly nations." Several developments from the Russian courts and government have apparently decimated the value of foreign IP in Russia, leaving U.S. companies holding patent portfolios in Russia scrambling to find a way to minimize the risk of infringement.
Listen as our authoritative panel of patent attorneys examines the implications of the recent U.S sanctions on Russia for patent owners and applicants. The panel will also address the steps that Russia has taken in response and what they mean for U.S. companies holding patents in Russia. Finally, the panel will discuss what U.S. companies might do to protect their patents and minimize the risk of infringement.
- U.S. sanctions on Russia
- Current state of the relationship between the USPTO and Rospatent and other relevant patent offices
- Russian response and implications for U.S. companies holding patents in Russia
- What U.S. companies might do to protect their patents and minimize the risk of infringement
- Best practices
The panel will review these and other key issues:
- What do the U.S. sanctions mean for maintaining patents in Russia?
- What are the implications of the USPTO breaking ties with the Russian Patent Office (Rospatent) and the Eurasian Patent Office?
- What steps can U.S. companies and their counsel take to minimize the risks of infringement?
Related Courses
Patent Design Arounds: Minimizing Risk of Infringement and Reducing Likelihood of Competitor Design Arounds
Monday, May 19, 2025
1:00 p.m. ET./10:00 a.m. PT
Patent Infringement: Structuring Opinions of Counsel
Wednesday, May 7, 2025
1:00 p.m. ET./10:00 a.m. PT
Means-Plus-Function Patent Claims Following Xencor: Preamble, Written Description, and More
Thursday, May 15, 2025
1:00 p.m. ET./10:00 a.m. PT